Although various studies describe the effects of incretin-related drugs on vascular endothelial function, we previously reported that neither sitagliptin nor liraglutide improve flow-mediated dilatation (FMD) in patients with type 2 diabetes [14, 15]. This evidence concerns the gene GCG and type 2 diabetes mellitus.